New Antithrombotic Drugs in Acute Coronary Syndromes: the Role of Fondaparinux and Bivalirudin in Reducing Major Hemorrhages and Mortality
DOI:
https://doi.org/10.2015/hc.v3i4.285Abstract
Two newer antithrombins have recently been tested for efficacy and safety in the treatment of acute coronary syndromes (ACS), an indirect antithrombin, fondaparinux, a synthetic pentasacharide with anti-Xa properties, and a direct thrombin inhibitor, bivalirudin, having an anticoagulant effect against both free and clot-bound thrombin. Both these newer antithrombotic agents are recommended in current guidelines as anthithrombotic therapies in ACS patients with their main advantage being increased safety due to reduced bleeding events.Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
